CEO Kapusta’s RSU Vesting at uniQure NV Sparks Mixed Signals Amid Market Slide and Legal Uncertainty

Insider Activity at uniQure NV: What the Latest Deal Tells Investors

The most recent insider transaction filed by CEO and Managing Director Kapusta Matthew C on March 4, 2026 shows the purchase of 70,600 restricted share units (RSUs) under the 2014 Share Incentive Plan. While the units vest over three years, the immediate effect is a modest increase in the CEO’s on‑balance‑sheet holdings, bringing his post‑transaction stake to 675,239 shares. The concurrent sale of 14,581 ordinary shares to cover withholding taxes (at an average price of $9.06) keeps the net position largely unchanged, suggesting that the purchase is largely a vesting event rather than a discretionary buy.

Implications for Investors

The timing of the RSU vesting—coincident with a sharp 22.6% weekly decline and a 55.2% monthly slide—raises questions about management’s confidence in the company’s near‑term trajectory. UniQure’s market cap of roughly €981 million and a negative P/E of –2.7 indicate a company still under pressure to demonstrate revenue growth, especially after recent analyst downgrades and the pending class‑action lawsuit. The CEO’s decision to lock in more shares at the current valuation, however, could be interpreted as a vote of confidence in the long‑term gene‑therapy pipeline. Investors who view the biotech sector’s valuation compression as a buying opportunity may see this insider activity as a signal that senior management believes the stock is undervalued.

What the Broader Insider Activity Reveals

Beyond the CEO, the latest filings show three other executives—Chief Medical Officer Abi‑Saab, Chief Legal Officer Potts, and Chief Financial Officer Klemt—each executing three trades. All three bought substantial block sizes of ordinary shares (ranging from 35,400 to 67,200) while also selling smaller amounts (mostly around 3,400–12,000 shares) at the prevailing $9.06 price. These patterns suggest a coordinated effort to increase exposure while managing tax liabilities, mirroring the CEO’s own strategy of vesting RSUs and selling a portion for tax coverage. The consistency across senior management may dampen concerns that the CEO’s trade is an isolated anomaly.

Kapusta Matthew C: A Profile of Historical Behavior

Examining Kapusta’s trading history over the past few months reveals a cautious yet consistent approach. He sold 34,437 shares on March 2 and 12,378 shares on February 25, both at prices well above the market average (¥9.95 and ¥23.86, respectively). The February sale occurred when the share price was near its 52‑week low of €7.21, suggesting a willingness to divest during downturns. Yet the March RSU purchase—an entirely non‑discretionary vesting event—highlights a pattern of aligning personal holdings with the company’s long‑term incentive structure rather than speculative short‑term gains. Over the past year, Kapusta’s total shareholdings have remained stable around 600,000–700,000 shares, reflecting a long‑term ownership stance.

Bottom Line for Market Participants

For investors eyeing uniQure, the insider activity underscores a mixed signal: the CEO and other executives are reinforcing their long‑term stake while managing tax implications, yet the stock remains under pressure from recent analyst downgrades and a looming lawsuit. If the management team’s confidence in the gene‑therapy pipeline translates into tangible clinical milestones, the current insider buys could precede a rebound. Until then, the consensus sentiment remains cautious, and any investment decision should weigh the company’s volatile valuation against its promising therapeutic portfolio.